Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
Apr 19, 2018
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.
Ovarian Cancer
FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
Apr 11, 2018
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer
Mar 29, 2018
A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.
Trial Participation May Offset Disparities in Ovarian Cancer Care
Mar 27, 2018
A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial.
Despite Evolving Treatment for Ovarian Cancer, Late Diagnosis Remains a Challenge
Mar 23, 2018
PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.
Possible Hereditary Link Between Ovarian and Testicular Cancers Observed
Mar 20, 2018
A registry study suggests that there may be a familial association between ovarian and testicular cancers.
Metformin, Statins Not Linked With Ovarian Cancer Risk in Diabetic Patients
Mar 16, 2018
A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.
Updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening
Mar 7, 2018
In this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.
COUNTERPOINT: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?
Feb 15, 2018
There will be no further randomized phase III trials of cytotoxic IP chemotherapy; IP therapy in ovarian cancer will soon be an historical footnote along with other failed approaches in cancer care.
POINT: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?
Feb 15, 2018
Intraperitoneal (IP) chemotherapy is a reasonable treatment approach for ovarian cancer because it can directly expose the surface tissues to which the cancer has disseminated to an extremely high concentration of the chemotherapy drug.